Duodenal Mucosal Resurfacing Cuts HbA1c in T2DM

Share this content:
Duodenal Mucosal Resurfacing Cuts HbA1c in T2DM
Duodenal Mucosal Resurfacing Cuts HbA1c in T2DM

THURSDAY, Aug. 18, 2016 (HealthDay News) -- Single-procedure duodenal mucosal resurfacing (DMR) is effective for reducing glycated hemoglobin (HbA1c) in patients with type 2 diabetes, according to a study published online Aug. 12 in Diabetes Care.

Harith Rajagopalan, M.D., Ph.D., from Fractyl Laboratories Inc. in Waltham, Mass., and colleagues used novel balloon catheters to conduct DMR on varying lengths of duodenum in anesthetized patients with type 2 diabetes. Twenty-eight patients had a long duodenal segment (LS) ablated, and 11 had a short segment (SS) ablated.

The researchers found that DMR was well tolerated with minimal post-procedure gastrointestinal symptoms. Duodenal stenosis was experienced by three patients, who were treated successfully by balloon dilation. In the full cohort, HbA1c was reduced by 1.2 percent at six months (P < 0.001). The LS cohort had a more potent glycemic effect, with 2.5 percent reduction in mean HbA1c versus 1.2 percent in the SS group (P < 0.05) at three months postprocedure and 1.4 versus 0.7 percent reduction in HbA1c at six months (P = 0.3). HbA1c was reduced by 1.8 percent at six months among LS patients with a screening HbA1c of 7.5 to 10 percent and on stable antidiabetic medications postprocedure.

"Single-procedure DMR elicits a clinically significant improvement in hyperglycemia in patients with type 2 diabetes in the short-term, with acceptable safety and tolerability," the authors write.

Several authors disclosed financial ties to biopharmaceutical companies, including Fractyl Laboratories, which funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

USPSTF Urges Abuse Screening for Reproductive-Aged Women

USPSTF Urges Abuse Screening for Reproductive-Aged Women

Evidence lacking for assessing balance of benefits, harms of screening for abuse of seniors, vulnerable

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Increased likelihood of clinical and microbiological resolution for uncomplicated UTI in women

Exercise Intervention Doesn't Improve Walking Ability in PAD

Exercise Intervention Doesn't Improve Walking Ability in PAD

Smaller mean change from baseline to follow-up in 6-minute walking distance with exercise intervention

is free, fast, and customized just for you!

Already a member?

Sign In Now »